A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease

Authors
Farlow, M Anand, R Messina, J Hartman, R Veach, J
Citation
M. Farlow et al., A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease, EUR NEUROL, 44(4), 2000, pp. 236-241
Citations number
10
Categorie Soggetti
Neurology,"Neurosciences & Behavoir
Journal title
EUROPEAN NEUROLOGY
ISSN journal
00143022 → ACNP
Volume
44
Issue
4
Year of publication
2000
Pages
236 - 241
Database
ISI
SICI code
0014-3022(2000)44:4<236:A5SOTE>2.0.ZU;2-M
Abstract
The efficacy of a centrally active cholinesterase inhibitor, rivastigmine t artrate (ENA 713; Exelon(R)), in patients with mild to moderately severe Al zheimer's disease was evaluated in a 26-week open-label extension of a 26-w eek, double-blind, placebo-controlled study. By 52 weeks, patients original ly treated with 6-12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo. Copyright (C) 2000 S. Karger AG., Basel.